HIV therapeutics, continued: another HIV protease inhibitor approved.
Laurence
Jeffrey
J
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D000069446:Atazanavir Sulfate; D018791:CD4 Lymphocyte Count; D017277:Drug Approval; D024882:Drug Resistance, Viral; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced; D006937:Hypercholesterolemia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use*; D018579:Patient Selection; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D019562:Viral Load
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate